ArticleCureus2025
Hydroxychloroquine-Induced Cardiomyopathy in a Young Female With Systemic Lupus Erythematosus: A Case Report.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of suspected hydroxychloroquine-induced cardiomyopathy: From therapy to toxicity.JHLT open · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydroxychloroquine (HCQ) is widely used in the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases due to its immunomodulatory and anti-inflammatory properties. Although generally well-tolerated, rare cases of HCQ-induced cardiomyopathy have been reported, often leading to irreversible cardiac dysfunction. We present a case of a 21-year-old female with SLE and biopsy-proven class II lupus nephritis who developed reversible cardiomyopathy associated with HCQ use. Prompt discontinuation of HCQ and initiation of guideline-directed medical therapy (GDMT) resulted in normalization of cardiac function. This case underscores the importance of early recognition and management of HCQ-induced cardiomyopathy, as well as the need for close cardiovascular monitoring in patients on long-term HCQ therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.